Biomarkers
Issued Date
2025-12-01
Resource Type
eISSN
15525279
Scopus ID
2-s2.0-105025833534
Pubmed ID
41452241
Journal Title
Alzheimer S Dementia the Journal of the Alzheimer S Association
Volume
21
Rights Holder(s)
SCOPUS
Bibliographic Citation
Alzheimer S Dementia the Journal of the Alzheimer S Association Vol.21 (2025) , e102473
Suggested Citation
Senanarong V., Thientunyakit T., Rattanabannakit C., Wongkom N., Dujada P., Raksthaput A., Chaichanettee S., Phoyoo P., Wachirutmangur L., Scheltens P. Biomarkers. Alzheimer S Dementia the Journal of the Alzheimer S Association Vol.21 (2025) , e102473. doi:10.1002/alz70856_102473 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113763
Title
Biomarkers
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND: Our objective of this study is to identify suitable local cut-off values of plasma-based biomarkers in Alzheimer disease (AD) in the discrimination of AD and non-AD subgroups in Thai population. METHOD: We conducted a prospective study in 51 individuals with clinically diagnosed AD (15 had amyloid PET positive (≥ 30 centiloid, CL), 16 had CSF Aβ42 ≤547 pg/mL and CSF pTau 181 >57 pg/mL regarded as amyloid positive AD), 34 individuals with clinically diagnosed non-AD dementia (9 had amyloid PET negative, 25 had CSF Aβ42 and CSF pTau181 negative), and 12 individuals with mild cognitive impairment (MCI) or normal controls (6 had amyloid PET negative and 6 had CSF Aβ42 and CSF pTau181 negative). Aβ-PET using 18F-florbetapir and plasma biomarkers (Aβ40, Aβ42, p-tau181, pTau 217, Glial fibrillary acidic protein (GFAP)) were obtained in all subjects within 6 months before or after the PET study. The quantitative analysis of Aβ-PET to obtain Centiloid (CL) followed the standard method using the SPM8 pipeline. Blood biomarker analysis utilized Simoa® Quanterix immunoassay. CSF Aβ42, t-Tau and p-Tau were measured separately, in duplicate, by commercially available sandwich ELISA kits (Innotest; Innogenetics/Fujirebio, Ghent, Belgium). Participants underwent a standardized diagnostic dementia evaluation. RESULT: Among 97 individuals, 54 (55.7%) amyloid positive and 43(44.3%) amyloid negative individuals were included in this blood biomarkers validation study. Mean age was 65.86(8.01) years, mean TMSE was 19.57(7.44) and mean MOCA was 15.48(7.27). Mean(SD) plasma Aβ 42/40, pTau181, pTau 217, NFL, and GFAP were 0.054(0.013) pg/mL, 37.591(18.975) pg/mL, 1.088(0.949) pg/mL, 102.703(412.308) pg/mL, and 162.459(107.223) pg/mL respectively. Utilizing single cut off from ROC analysis: the cut off points are as followed; for plasma Aβ42/40≤0.054pg/mL (AUC(SE)=0.716(0.064), p <0.0001, accuracy 72.63(62.52-81.28)); plasma pTau181>32.7pg/mL (AUC(SE)=0.812(0.058), p <0.0001, accuracy73.20(63.24-81.68)); plasma pTau217>0.522pg/mL (AUC(SE)=0.856(0.056), p <0.0001, accuracy87.14(76.99-93.95)); GFAP>119pg/mL (AUC(SE)=0.796(0.058), p <0.0001, accuracy77.89(68.22-85.77)). For high and low cut- points, the results were shown in table 1. CONCLUSION: Plasma biomarkers showed promising diagnostic performances and potential clinical usefulness in diagnosing dementia. Plasma p-tau217 was best differentiates AD positive from AD negative groups, followed by plasma GFAP, pTau181, and Aβ42/40 ratio. Thank you Health Systems Research Institute (Thailand) grant support for this study.